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Identification of tetrahydrocarbazoles as novel multifactorial
drug candidates for treatment of Alzheimer’s disease
K Honarnejad1,2,3,7, A Daschner1,2, AP Gehring4, A Szybinska5, A Giese2, J Kuznicki5, F Bracher4 and J Herms1,2,6
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder and the most frequent cause of dementia. To date, there
are only a few approved drugs for AD, which show little or no effect on disease progression. Impaired intracellular calcium
homeostasis is believed to occur early in the cascade of events leading to AD. Here, we examined the possibility of normalizing the
disrupted calcium homeostasis in the endoplasmic reticulum (ER) store as an innovative approach for AD drug discovery. High-
throughput screening of a small-molecule compound library led to the identification of tetrahydrocarbazoles, a novel multifactorial
class of compounds that can normalize the impaired ER calcium homeostasis. We found that the tetrahydrocarbazole lead structure,
first, dampens the enhanced calcium release from ER in HEK293 cells expressing familial Alzheimer’s disease (FAD)-linked presenilin
1 mutations. Second, the lead structure also improves mitochondrial function, measured by increased mitochondrial membrane
potential. Third, the same lead structure also attenuates the production of amyloid-beta (Aβ) peptides by decreasing the cleavage
of amyloid precursor protein (APP) by β-secretase, without notably affecting α- and γ-secretase cleavage activities. Considering the
beneficial effects of tetrahydrocarbazoles addressing three key pathological aspects of AD, these compounds hold promise for the
development of potentially effective AD drug candidates.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly.1 Currently, there is no effective therapeutic modality
for the prevention, halting or reversal of AD.2 The two principal
neuropathological hallmarks of AD are the accumulation of
extracellular plaques of β-amyloid (Aβ) peptides and intracellular
neurofibrillary tangles of hyperphosphorylated tau protein in the
brain. Aβ and tau are thus the prime drug targets for development
of disease-modifying therapy in AD.1 Nevertheless, the lack of
breakthroughs in effective therapy, along with the consistent
failure of drug candidates targeting late-stage Aβ and tau
pathologies in clinical trials, have recently led to a major shift
towards the search for alternative AD drug targets.3 Importantly,
dysregulated calcium signaling has a central role in AD
pathogenesis,4,5 for example, by triggering both Aβ and tau
pathology.6,7 Indeed, calcium imaging of AD patient-derived cells8
and of neurons from transgenic AD mouse models9 indicate that
disturbances in endoplasmic reticulum (ER) calcium homeostasis
are early events in AD pathogenesis, most likely preceding the
clinical manifestations of the disease.10 Practically, every gene that
is known to directly cause AD or increase susceptibility to it,
somehow also affects calcium homeostasis.4 Hence, therapeutic
interventions aiming at preventing such early calcium dysho-
meostasis have been proposed to present a promising opportu-
nity for disease-modifying therapy of AD.11 Indeed,
pharmacological normalization of ER calcium homeostasis was
shown to lower Aβ burden and restore synaptic and cognitive
functions in a number of AD mouse models.12–14 Furthermore, due
to the multifactorial involvement of ER in the pathogenesis of AD,
even minimal levels of therapeutic modulation in the ER may yield
tremendous therapeutic efficacy.15 In light of such indications and
the novelty of this approach, we developed and performed a high-
throughput screen for small-molecule compounds that can
normalize the enhanced agonist-evoked ER calcium release
phenotype in HEK293 cells expressing FAD-linked Presenilin-1
(PS1) mutations. Various mechanisms have been proposed to
underlie the FAD-PS1-mediated enhancement of the ER calcium
release, for example, enhanced inositol 1,4,5-trisphosphate (IP3)
receptor and ryanodine receptor (RyR) channel activities, altered
sarcoendoplasmic reticulum calcium transport ATPase (SERCA)
pump function, decreased capacitative calcium entry and loss of
ER passive calcium leakage.16 Aside from the controversies in the
field as to which of these are the primary causative and which the
secondary phenomena, we performed a large-scale phenotypic
compound screening. This resulted in the identification of a novel
class of chemical structures that normalize the exaggerated
calcium release from ER in cells expressing a FAD-PS1 mutation.
Stabilization of calcium signaling by the identified lead structure
was accompanied by improved mitochondrial function and
decreased Aβ peptide production.
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MATERIALS AND METHODS
Cell culture and cell lines
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco’s
modified eagle medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin while being incubated at 37 °C, 5% CO2 and
90% humidity. The stable PS1 lines (generously provided by Dr S Lammich)
were carrying PS1 variants that were cloned into pcDNA3.1/Zeo(+) and
single cells were selected via Zeocin antibiotic resistance.17 The PS1 lines
were then stably transfected with Yellow Cameleon 3.6 (YC3.6)/pcDNA3
construct (kindly provided by Dr A Miyawaki) and single cells were
respectively isolated by G418 antibiotic resistance leading to the
generation of double stable lines. The amyloid precursor protein (APP)-,
C99- and APPsw/PS1-M146L-overexpressing HEK293 lines were kindly
provided by Dr S. Lichtenthaler and Dr H. Steiner and cultured as
previously described.18,19
Automated high-throughput FRET-based calcium imaging and
image analysis
HEK293 cells stably expressing PS1-M146L and YC3.6,20 were seeded at
13 000 cells per well in 40 μl of growth medium on collagen-coated 384-
well CellCarrier plates (Perkin Elmer, Rodgau, Germany). After 6 h, using an
automated pipetting robot (Bravo, Agilent Technologies, Santa Clara, CA,
USA), library compounds were added to each well at the final
concentration of 10 μM in 1% dimethyl sulfoxide (DMSO), each in four
replicates. All plates contained Thapsigargin (TP; 1 μM; Calbiochem,
Darmstadt, Germany), cyclopiazonic acid (CPA; 20 μM; Calbiochem), 3,4,5-
trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8; 50 μM; Sigma-
Aldrich, Taufkirchen, Germany) and Bepridil (20 μM; Sigma-Aldrich) as
positive controls reducing the amount of calcium release from ER, as well
as untreated and DMSO vehicle-treated wells. After 24 h using the
pipetting robot, DRAQ5 (Biostatus, Leicestershire, UK), a far-red fluorescent
nuclear dye, was added to each well at the final concentration of 500 nM.
After 2 h, plates were measured for carbachol (CCh)-induced calcium
release using Opera high-throughput confocal imaging platform (Perkin
Elmer Cellular Technologies GmbH, Hamburg, Germany). Throughout
imaging of the entire plate, 37 °C temperature, 5% CO2 and 90% humidity
was maintained in the plate chamber. Using a 442 nm laser, YC3.6 was
excited and its CFP and YFP emissions were separated, respectively, using
483/35 nm and 540/75 nm filters. In addition, using a 640 nm laser, DRAQ5
dye was excited and its emission was collected by 690/50 nm filter to
locate the nuclei. Imaging was performed with a × 20 water immersion
autofocus objective. The duration of the entire time-lapse calcium imaging
for each well was 23.5 s. This was achieved by imaging at 2.5 s interval
resolution before dispensing CCh (for 5 s) to monitor the basal calcium
levels. Next, the CCh-induced calcium rise and decay were monitored for
18.5 s post dispensing. Imaging was performed first at 1 s interval
resolution immediately after dispensing (for 5 s) and subsequently at
2.5 s interval resolution (for 12.5 s). During dispensing, 10 μl of CCh
(Calbiochem) diluted in HBSS (10 μM) was injected to each well concurrent
with calcium imaging by an automated dispensing unit which is part of the
Opera platform. Imaging was performed sequentially for all the 384 wells.
Using Acapella software (Perkin Elmer Cellular Technologies GmbH), an
automated image analysis tool was developed to convert fluorescent
signals to numerical values. Here, DRAQ5 and YC3.6 signals were used,
respectively, to detect single-cell nuclei and single-cell boundaries over the
entire course of time-lapse calcium imaging. After assigning each cell to its
segmented nuclei and excluding the cells positioned at the edges of the
imaging frames, calcium transients for every cell were monitored by
plotting the kinetics of YFP/CFP versus time and normalizing the signals
using the equation, ΔF/F0 = (F− F0)/F0, where F is the measured fluores-
cence signal at any given time and F0 is the average fluorescence signal of
the time points preceding CCh application. The peak amplitude of calcium
rise upon CCh injection was the output of automated image analysis at
single-cell level. Nonresponsive cells to CCh were excluded from analysis
by setting an arbitrarily defined threshold. The average peak amplitude of
all responsive cells in each well was calculated as the final readout in
this assay.
Mitochondrial membrane potential TMRM assay
The measurement method for mitochondrial membrane potential with
tetramethylrhodamine methyl ester (TMRM) dye was adapted from
Scaduto et al.21 HEK293 cells were seeded at the density of 50 000 cells
per well on collagen/poly-L-lysine (PLL)-coated 96-well plates (Advanced-
TC plates, Greiner Bio-One GmbH, Frickenhausen, Germany) and incubated
for 24 h. Next, the cells were loaded with 50 nM TMRM (Invitrogen,
Carlsbad, CA, USA) dye in the presence of either tetrahydrocarbazoles
(10 μM), positive control Dimebon (10 μM; Sigma-Aldrich) or DMSO vehicle,
which were pre-incubated on the cells 1 h before the addition of TMRM
dye. After 30min, each well was washed three times using phosphate-
buffered saline. Fresh medium containing each of the corresponding
tested compounds (10 μM) was added into the wells. Live cell image
acquisition was performed using inverted confocal microscope LSM510
with × 25 magnification (Carl Zeiss MicroImaging GmbH, Jena, Germany)
and the images were analyzed using ImageJ software (NIH, Bethesda, MD,
USA) to quantify the intensity of TMRM fluorescence signal. All the
measurements were performed with at least eight replicates.
Aβ measurements
The levels of three different Aβ species (Aβ38, Aβ40 and Aβ42) were
measured using sandwich enzyme-linked immunosorbent assay (ELISA).
Pools of HEK293 cells stably transfected with either APPsw/PS1-M146L or
APP were used to study the effect of compounds on Aβ generation.
According to Page et al.,19 cells were seeded at a density of 200 000 cells
per well in collagen/poly-L-lysine (PLL)-coated 24-well plates and
incubated for 24 h in the growth medium. Next, the medium was
exchanged with 500 μl of fresh medium containing either the tested
compounds, or the positive controls DAPT (10 μM, Calbiochem), Sulindac
sulfide (50 μM, Sigma-Aldrich), Bepridil (30 μM, Sigma-Aldrich)18 or DMSO
vehicle. After 16 h conditioned medium was collected and the levels of
secreted Aβ38, Aβ40 and Aβ42 fragments were quantified using ‘Human
(6E10) Abeta 3-Plex’ sandwich ELISA immunoassay kit (Meso Scale
Discovery, Rockville, MD, USA) according to the instructions of the
manufacturer. In brief, 150 μl of blocker reagent was added to each well
and incubated for 1 h at room temperature, followed by 3 × washing using
TRIS wash buffer. Next, 25 μl of detection antibody was added to each well.
At appropriate dilution, each of the samples or calibration standards were
added to separate wells of ELISA plate and incubated for 2 h at room
temperature, followed by 3 × washing using TRIS wash buffer. Finally,
150 μl of read buffer was added to the wells. The light emission after
electrochemical stimulation was measured using Sector Imager 2400
reader (Meso Scale Discovery). On the basis of the values generated with
calibration standards, corresponding concentrations of Aβ species were
calculated using the Meso Scale Discovery Workbench software. All the
measurements were performed with at least two replicates.
sAPPα and sAPPβ measurements
Levels of sAPPα and sAPPβ fragments were measured using sandwich
ELISA adapted from Colombo et al.22 Wild-type HEK293 cells were seeded
at a density of 200 000 cells per well in collagen/poly-L-lysine (PLL)-coated
24-well plates and incubated for 24 h in the growth medium. Next, the
medium was exchanged with 500 μl of fresh medium containing either
compounds or vehicle. After 16 h, conditioned medium was collected and
the levels of secreted sAPPα and sAPPβ fragments were quantified using
sAPPα/sAPPβ sandwich ELISA immunoassay kit (Meso Scale Discovery)
according to the instructions of the manufacturer. Briefly, 150 μl of blocker
reagent was added to each well of the ELISA plate and incubated for 1 h at
room temperature, followed by 3 × washing using TRIS wash buffer. Next,
25 μl of samples or calibration standards were added to separate wells of
ELISA plate and incubated for 1 h at room temperature, followed by 3 ×
washing using TRIS wash buffer. Then, 25 μl of detection antibody was
added to each well and incubated for 1 h at room temperature, followed
by 3 × washing using TRIS wash buffer. Finally, 150 μl of read buffer was
added to the wells. The light emission after electrochemical stimulation
was measured using Sector Imager 2400 reader (Meso Scale Discovery). On
the basis of the values generated with calibration standards, correspond-
ing concentrations of sAPPα and sAPPβ were calculated using the Meso
Scale Discovery Workbench software. All the measurements were
performed in four replicates.
Statistical data analysis
GraphPad Prism 5.0 b (GraphPad Software, San Diego, CA, USA) was used
for statistical analysis of the data. For comparison and P-value determina-
tion, we used one-way analysis of variance (ANOVA) method, followed by
Dunnett's multiple comparison test. All the data are represented as
means± s.d. Differences were considered statistically significant if Po0.05.
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RESULTS
Discovery of a novel lead structure from a high-throughput
compound screen targeting disrupted ER calcium homeostasis
In light of growing evidence towards the role of impaired
intracellular store calcium homeostasis in the pathogenesis of
Alzheimer’s disease,23 here, we screened for low-molecular-weight
compounds that can normalize the disrupted ER calcium home-
ostasis. We chose the potentiated agonist-evoked ER calcium
release in FAD-PS1-expressing cells as a robust phenotypic model
to target ER calcium dyshomeostasis for AD drug discovery.
All mutant PS1 lines tested revealed remarkably enhanced
calcium release when compared with wild-type PS1-expressing
cells (Figure 1a). A phenotypic screening for compounds that are
capable of dampening the potentiated CCh-evoked ER calcium
release in PS1-M146L HEK293 cells was subsequently performed.
Screening a diverse compound library comprising 20 000 small
molecules led to the discovery of 1-amino-1,2,3,4-tetrahydrocar-
bazoles as a novel lead structure. Six recognized representatives of
this structural motif in the library which showed activity in the
screen (Figure 1b), remained active across several other mutant
PS1-expressing lines (Figures 1c–e). Importantly, the amplitude of
CCh-evoked calcium release in wild-type PS1-expressing cells was
not significantly altered (Figure 1f). For the primary screen, a
compound was regarded as active if it reduced the peak
amplitude of CCh-induced calcium release to o90% of DMSO-
treated controls (normalized ER calcium o0.9).
The discovered lead structure, identified as and hereafter called
tetrahydrocarbazoles, consists of a core moiety having two
variable R groups, shown as R1 and R2 (Figure 1g). Comprehensive
data mining revealed that the entire compound library contained
10 analogs of the lead structure, 8 of which were found to be
active in the screen (Figure 1g).
Tetrahydrocarbazoles attenuate the FAD-PS1 mediated
exaggerated ER calcium release
In order to explore the contribution of different R1 and R2 groups
to the activity of the lead structure, we further tested 28
commercially available tetrahydrocarbazole analogs and related
structures. We also validated the activity of the 10 structures
previously identified from the primary screen (Figure 2a and
Supplementary Figure S1). On the basis of the structure–activity
relationship knowledge gained, we synthesized 23 further
derivative structures with the aim of reaching an improved
efficacy (Figure 2b and Supplementary Figure S2; for details about
the synthesis, see Supporting Information). Replacement of nitro
group at R1 position with other electron-withdrawing substituents,
for example, halogens, trifluoromethyl and cyano groups, main-
tains the activity of the lead structure, while other small
substituents, for example, hydrogen, lead to the loss of activity.
Aliphatic residues at R2 position (for example, 5781439, 5781448,
5781457, gea_87) diminish that effect, while additional attach-
ment of an aromatic motif (for example, phenyl group) is
beneficial to the activity (for example, 5781464, 5781441).
Tetrahydrocarbazoles increase the mitochondrial membrane
potential
It has been demonstrated that ER and mitochondria are physically
and functionally interdependent.24 Constitutive calcium release
from IP3R to mitochondria is a crucial mechanism involved in
mitochondrial function.25 Indications suggest that FAD-PS muta-
tions affect the physical interaction between ER and
mitochondria,26 leading to altered shuttling of calcium between
the two organelles and modulating the mitochondrial calcium
uptake.27 Thus, in the next set of experiments, we explored
whether the modulation of ER calcium homeostasis by the lead
structure also affects mitochondrial function. To that end, we
analyzed mitochondrial membrane potential as an important
parameter for addressing mitochondrial activity. We used TMRM
dye, a fluorescent rhodamine derivative, to monitor mitochondrial
membrane potential.21 Indeed, pretreatment of HEK293 cells for
1 h with several tetrahydrocarbazoles led to a remarkable increase
in the mitochondrial membrane potential, measured by the TMRM
fluorescence signal (Figures 3a and b). At 10 μM, the increases in
mitochondrial membrane potential after treatment with many of
the analogs were comparable or even superior to that for
Dimebon, a known enhancer of mitochondrial activity28 (Figures
3a and b). We particularly found that compounds 5781464 and
5781441, respectively, possessing N-(1-benzylpiperidin-4-yl) and
N-(1-phenethylpiperidin-4-yl) groups at their R2 position, were
among the most active compounds both in terms of efficacy and
potency (Figures 3b and d). Therefore, in several lead structure
derivatives that we synthesized, the R2 position remained
incorporating N-(1-benzylpiperidin-4-yl) or N-(1-phenethylpiperi-
din-4-yl) groups, whereas we varied the groups at the R1 position
to explore their influence on the activity of the lead structure
(Supplementary Figure S2). Indeed the latter analogs were also
among the most active synthesized compounds in enhancing
mitochondrial function (Figure 3c). Therefore, we concluded that
the highest activity in terms of improving mitochondrial
membrane potential is achieved if the lead structure possesses
N-(1-benzylpiperidin-4-yl) or N-(1-phenethylpiperidin-4-yl) groups
at the R2 position, given that the R1 position incorporates electron-
withdrawing residues. Exemplarily, the EC50 for one of the most
promising synthesized derivatives of the lead structure (gea_133;
R1: cyano) was determined to be at the therapeutically relevant
value of 4.84 μM (Figure 3d). Moreover, the efficacy of compound
gea_133 was remarkably higher than Dimebon, especially at
concentrations beyond 1 μM (Figure 3d).
Tetrahydrocarbazoles lower Aβ peptide production
FAD-PS mutations are well known to promote the production of
Aβ42 peptide.29 Therefore, next, we studied the impact of
tetrahydrocarbazoles on the production of Aβ peptides. Modula-
tion of intracellular calcium homeostasis directly affects Aβ
production.30 Thus, we hypothesized that normalizing the
disrupted ER calcium homeostasis may additionally result in
lowered Aβ production. Indeed, we detected remarkably
decreased levels of secreted Aβ38, Aβ40 and Aβ42 peptides upon
16 h treatment of HEK293 cells expressing either APPsw/PS1-
M146L or wild-type APP with the lead structure analogs at 10 μM
(Figures 4a and c and Supplementary Figure S3). The IC50 of the
select promising analogs in terms of decreasing levels of all three
Aβ species lies in the low micromolar range (Figures 5b–d).
However, compound treatment in both the cell lines did not affect
the Aβ42/Aβ40 ratio for most analogs, suggesting that the
identified lead structure is not a γ-secretase modulator (Figures
4b and d and Supplementary Figure S4). To investigate the γ-
cleavage of APP independently from its β-cleavage, we used
HEK293 cells expressing C99, the β-cleaved carboxy (C)-terminal
fragment of APP and the substrate for γ-secretase. Here, we
observed that treatment of HEK293-C99 cells with the majority of
the tetrahydrocarbazoles tested, did not (or only marginally) affect
the production of Aβ38, Aβ40 and Aβ42 (Figure 6a). Moreover,
Aβ42/Aβ40 ratios remained unaffected upon exposure of HEK293-
C99 cells with the tetrahydrocarbazoles (Figure 6b). Taken
together, these results support the conclusion that the detected
decrease in Aβ peptide levels is not a γ-secretase-dependent
phenomenon. In accordance, we postulated that reduced β-
cleavage of APP may contribute to lowered Aβ generation. Hence,
we measured the levels of sAPPα and sAPPβ, the first cleavage
products of APP, generated by α-secretase and β-secretase,
respectively. Indeed, we detected significantly decreased levels
of secreted sAPPβ, while sAPPα levels were mostly unaffected (or
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Figure 1. Tetrahydrocarbazole analog screening hits/lead structure and their effects on FAD-PS1-mediated disrupted ER calcium release. (a)
The peak amplitude of CCh-evoked calcium release in HEK293 cells expressing wild-type PS1, FAD-linked (PS1-M146L, PS1-C92S and PS1-
DeltaE9) or a γ-secretase deficient (PS1-D385N) PS1 mutations. The effect of six tetrahydrocarbazole hits identified from the primary screen at
10 μM in (b) PS1-M146L, (c) PS1-C92S, (d) PS1-DeltaE9, (e) PS1-D385N and (f) wild-type PS1-expressing HEK293 cells on the peak amplitude of
CCh-evoked calcium release. CPA, an inhibitor of calcium-dependent ATPases, was used as a positive control. (g) The tetrahydrocarbazole lead
structure, identified from a high-throughput compound screen for substances normalizing the exaggerated CCh-evoked calcium release in
PS1-M146L HEK293 cells. Illustrated are chemical structures of the 10 tetrahydrocarbazole analogs present in the entire screened compound
library. The upper and lower panels indicate, respectively, eight active and two inactive analogs of the lead structure. Compounds capable of
reducing the peak amplitude of CCh-induced calcium release to o90% of DMSO-treated controls (normalized ER calcium o0.9) were
regarded as active hits. (n.s., non-significant; ***Po0.001; n= 4). CCh, carbachol; CPA, cyclopiazonic acid; DMSO, dimethyl sulfoxide; ER,
endoplasmic reticulum; FAD-PS1, familial Alzheimer’s disease presenilin 1.
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only mildly reduced) upon treatment of wild-type HEK293 cells
with the tested substances (Figure 4e). These results imply that the
attenuated Aβ production caused by the compounds is mediated
through decreased cleavage of APP by β-secretase. The structure–
activity relationship analysis among the lead structure analogs in
terms of lowering Aβ production was comparable to their
determined structure–activity relationship for increasing mito-
chondrial membrane potential. We found that analogs incorpor-
ating electron-withdrawing residues at the R1 position, in
combination with N-(1-benzypiperidin-4-yl) or N-(1-phenethylpi-
peridin-4-yl) at R2 position show the most robust reduction in Aβ
production (Figure 4a).
DISCUSSION
Dysfunction and loss of neurons and synapses are by far the best
available correlates of cognitive deficits in AD patients.31,32
Regulation of calcium homeostasis is essential for neuronal
function and synaptic activity.33 Early-stage aberrant calcium
signaling in AD is proposed to underlie the late-stage synaptic
dysfunction and memory deficits.34 Notably, alterations in ER
calcium channels were found to correlate with neurofibrillary and
Aβ pathologies of AD brain.7 Moreover, altered calcium home-
ostasis in the peripheral tissues was proposed as diagnostic
biomarkers of mild AD.35,36 Furthermore, the beneficial effects of
memantine, an NMDA receptor antagonist, for the treatment of
moderate-to-severe AD patients reinforce the relevance of
calcium-signaling-targeted AD therapy.37 Indeed, pharmacological
normalization of disrupted ER calcium homeostasis by blocking
hyperactivated RyR channels with dantrolene was demonstrated
to be associated with decreased Aβ burden, increased PSD-95
expression and improvements in learning and memory in APPsw-
expressing mouse model of AD.13 Altogether, given the central
role of calcium both in triggering the early disease-initiating
Figure 2. The effects of tetrahydrocarbazoles and analogs on the FAD-PS1-mediated enhanced ER calcium release. (a) The activity of
commercially available and (b) synthesized tetrahydrocarbazoles and analogs tested at 10 μM in PS1-M146L HEK293 cells. The presented
values indicate the normalized peak amplitude of CCh-evoked calcium release for cells treated with each compound for 24 h relative to the
peak amplitude of DMSO-treated control (normalized ER calcium). Compounds marked with # symbol possess a certain level of toxicity, which
interferes with the calcium release measurement in this assay. TP (1 μM), CPA (20 μM), TMB-8 (50 μM) and Bepridil (20 μM), all lowering the
amount of calcium release from ER, were used as positive controls. (n.s. non-significant; *Po0.05, **Po0.01 and ***Po0.001; n= 4). CCh,
carbachol; CPA, cyclopiazonic acid; DMSO, dimethyl sulfoxide; ER, endoplasmic reticulum; FAD-PS1, familial Alzheimer’s disease presenilin 1;
TMB, 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester; TP, Thapsigargin.
Tetrahydrocarbazoles as multifactorial AD drug candidates
K Honarnejad et al
5
Translational Psychiatry (2014), 1 – 11
pathomechanisms as well as accelerating the AD pathology at
later stages,38 targeting altered calcium signaling presents an
attractive target for both AD prevention and treatment. Accord-
ingly, we developed and performed a high-throughput screen for
compounds that can normalize the aberrant ER calcium home-
ostasis phenotype caused by FAD-linked PS1 mutations. This
approach led to the discovery of tetrahydrocarbazoles, a novel
lead structure capable of lowering the exaggerated CCh-evoked
ER calcium release in FAD-PS1 cells.
In addition to the stabilization of ER calcium homeostasis, we
observed that tetrahydrocarbazoles can improve mitochondrial
function, measured by increased mitochondrial membrane
potential. Mitochondrial dysfunction is proposed to act as a
trigger in AD pathogenesis and a contributing factor to both onset
and progression of the disease.39 In addition to aberrant calcium
homeostasis, mitochondrial dysfunction is an additional early
event in the course of AD, thus presenting an attractive target for
preventative therapy.40 FAD-PS1 mutations have been shown to
cause abnormal changes in mitochondrial morphology and
sensitivity to apoptosis upon mitochondrial failure.41,42 Neuronal
cells harboring FAD-PS1 display decreased mitochondrial mem-
brane potential under oxidative stress conditions.41 Yet another
study reported no significant relative mitochondrial membrane
potential differences between fibroblasts derived from FAD-PS1
mutation carriers versus controls.43 Growing body of evidence
indicates that the ER–mitochondria physical interfaces and
calcium shuttling between the two organelles through IP3
receptors have a crucial role in the regulation of mitochondrial
function,25 which appears to be affected in AD.26,27 Treatment
with many of the lead structure derivatives resulted in a larger
increase in the mitochondrial membrane potential than treatment
with Dimebon. The latter suggests higher efficacy for tetrahy-
drocarbazoles compared with Dimebon.
Extensive literature underlines the role of FAD-PS mutations in
altering the proteolytic processing of APP, which, in turn, leads to
selective increase in the formation of longer Aβ42 versus the
Figure 3. The effect of tetrahydrocarbazole analogs on mitochondrial membrane potential. (a) Representative TMRM-staining images of
HEK293 cells pretreated for 1 h with the indicated tetrahydrocarbazoles (10 μM) or Dimebon (10 μM) as a positive control, relative to DMSO-
treated control (scale bar, 100 μm). (b) Quantification of the average TMRM-staining signals showing relative intensity for commercially
available analogs of the tetrahydrocarbazole lead structure upon 1 h pretreatment of HEK293 cells (10 μM). The bars highlighted with single-
and double-stripes represent the most active compounds 5781464 and 5781441, which, respectively, possess N-(1-benzylpiperidin-4-yl) and N-
(1-phenethylpiperidin-4-yl) groups at their R2 position. (c) Quantification of average TMRM intensity for synthesized tetrahydrocarbazole
derivatives tested at 10 μM. The marked single-striped bars represent the analogous structures similar to 5781464, possessing N-(1-
benzylpiperidin-4-yl) at their R2 position, and double-striped bars represent derivative compounds similar to 5781441, which contain N-(1-
phenethylpiperidin-4-yl) group at the R2 position. (d) Quantification of average dose-dependent TMRM relative intensities for three select
tetrahydrocarbazoles tested at six different concentrations relative to Dimebon. The EC50 of all analogs tested lies at low micromolar range. All
the values are normalized to DMSO value, which is set to 1. (n.s., non-significant; *Po0.05, **Po0.01 and ***Po0.001; n= 8). DMSO, dimethyl
sulfoxide; TMRM, tetramethylrhodamine methyl ester.
Tetrahydrocarbazoles as multifactorial AD drug candidates
K Honarnejad et al
6
Translational Psychiatry (2014), 1 – 11
shorter Aβ40 peptides.29,44 We found that treatment with many
tetrahydrocarbazole analogs results in notably less Aβ38, Aβ40
and Aβ42 production in two different cell lines. Yet, Aβ42/Aβ40
ratios remained largely unchanged. The latter indicates that the
identified lead structure does not possess the properties of a γ-
secretase modulator. γ-Secretase modulators are characterized by
decreased production of longer Aβ species (for example, Aβ42)
accompanied by increased generation of shorter Aβ species (for
example, Aβ38 and Aβ40), resulting in the lowering of Aβ42/Aβ40
ratio.45 Although there is evidence that γ-secretase activity may be
affected by calcium ions,46 the detected decreases in Aβ levels
were not predominantly caused by γ-secretase inhibition. The
evidence for the latter comes from the experiments with HEK293-
C99 cells, suitable for exclusively addressing the γ-secretase
cleavage of APP (independently from β-secretase activity). In
HEK293-C99 cells, we detected unchanged or only slightly
decreased Aβ levels upon treatment with the derivative structures
tested. These minor reductions in Aβ levels caused by some lead
structure derivatives can be due to the fact that calcium ions can
modulate the γ-secretase activity to some extent.46 However, such
minor effects are unlikely to account for the remarkable decrease
in Aβ levels observed after the treatment of APPsw/PS1-M146L
and APP-expressing cells with tetrahydrocarbazole analogs. Our
findings rather suggest that lowered Aβ production is mainly
attributed to decreased β-cleavage of APP. We detected
remarkably decreased sAPPβ levels upon exposure of HEK293
cells with the lead structure derivatives. Indeed, it has been
demonstrated that calcium directly enhances the proteolytic
activity of β-secretase (BACE1).47 Therefore, it is plausible that the
stabilization of ER calcium homeostasis by tetrahydrocarbazoles
results in lowered BACE1 activity and consequently decreased Aβ
production. The decrease in sAPPβ was not accompanied by an
increase in sAPPα, indicating that the lead structure does not alter
the α-secretase cleavage activity. The lack of inverse coupling
between α- and β-secretase activities in frequently used cell lines,
for example, HEK293 cells, may explain our finding that the
compounds lower sAPPβ generation without changing sAPPα
levels.22 The observation that most tetrahydrocarbazoles do not
affect Aβ and sAPPα levels, respectively, in HEK293-C99 and wild-
type HEK293 cells (for example, gea_133), indicates that the
decreased Aβ production through lowering β-cleavage of APP is
indeed a specific effect, which is not caused by reduced protein
production.
Figure 4. The effect of tetrahydrocarbazoles on APP processing. (a) Relative Aβ38, Aβ40 and Aβ42 levels, decreased after 16 h treatment with
synthesized tetrahydrocarbazoles at 10 μM in HEK293 cells coexpressing APPsw and PS1-M146L. Sulindac sulfide (50 μM), a γ-secretase
modulator, and DAPT (10 μM), a γ-secretase inhibitor, were used as positive controls. Inside the box, a schematic illustration of APP processing
by α-, β- and γ-secretase is presented. (b) Relative Aβ42/Aβ40 ratios calculated from a. Treatment with the majority of tetrahydrocarbazoles
does not alter Aβ42/Aβ40 ratio, whereas positive control Sulindac sulfide significantly lowers Aβ42/Aβ40 ratio. (c) Relative Aβ38, Aβ40 and Aβ42
levels are decreased after 16 h treatment with select tetrahydrocarbazoles at 10 μM in HEK293 cells overexpressing wild-type APP. (d) Relative
Aβ42/Aβ40 ratios calculated from c. Treatment with select tetrahydrocarbazoles tested does not alter Aβ42/Aβ40 ratio. (e) Relative sAPPα and
sAPPβ levels after 16 h compound treatment in wild-type HEK293 cells. Treatment with select tetrahydrocarbazole derivatives does not (or
only marginally) affect secreted sAPPα levels, whereas secreted sAPPβ fragment levels are remarkably decreased. All the values are normalized
to the value of DMSO, which is set to 1. (n.s., non-significant; *Po0.05, **Po0.01 and ***Po0.001; n= 2). APP, amyloid precursor protein;
DMSO, dimethyl sulfoxide; PS1, presenilin 1.
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The structure–activity relationship analysis revealed that the
effect of lead structure analogs is most prominent with specific
residues at C-6 (R1) and the exocyclic amino group (R2). We found
that when R1 represents halogens and other electron-withdrawing
substituents, for example, nitro, trifluoromethyl and cyano, this
leads to a strong increase in mitochondrial membrane potential,
while also strongly attenuating Aβ peptide production and ER
calcium release. On the other hand, substitution at C-7 and C-8
(gea_84) was found to be detrimental to the activity. Furthermore,
N-methylation at either the pyrrole nitrogen (gea_90) or the side
chain secondary amino group (gea_92) led to the complete loss of
activity. Merely aliphatic residues at the exocyclic nitrogen (R2; that
is, 5781439, 5781448, 5781457, gea_87) result in lowering or loss
of the activity, whereas additional attachment of an aromatic
motif (phenyl group) shows benefit in all three assays (that is,
5781464, 5781441). The best effect in all the three assays was
detectable for tetrahydrocarbazoles containing a diamino side
chain R2 (4-aminopiperidine) with an attached N-benzyl or N-
phenethyl residue (that is, 5781441, 5781464, gea_96, gea_97,
gea_101, gea_102, gea_130, gea_133; Figure 5a). Therefore, by
systematic optimization of the primary screening hits, we
generated a subclass of compounds that are active in all the
three assays.
The vast majority of AD patients are sporadic late-onset cases
and age remains the main risk factor for developing sporadic
AD.48 Importantly, aging process involves disturbances in the
intracellular calcium homeostasis, particularly in ER and
mitochondria.49,50 Lymphocytes derived from sporadic AD
patients show elevated cytosolic basal calcium
concentrations.36,51 Every gene that is known to increase
susceptibility to AD also modulates some aspect of calcium
signaling.4 In particular, a polymorphism in the CALHM1 gene
encoding an ion channel’s pore-forming subunit that affects
intracellular calcium homeostasis, has been linked to susceptibility
to sporadic AD.52,53 Along with the ER stress, mitochondrial
damage also contributes to aging process.54 Moreover, sporadic
AD is associated with reduced mitochondrial membrane
potential,55 as well as elevated BACE1 activity,56 which, in turn,
leads to increased Aβ production and plaque deposition.57
Therefore, we predict that the benefits of tetrahydrocarbazoles,
will not be limited to familial AD cases, but also may present a
high potential for sporadic AD cases as well (patent pending; PCT/
EP2013/055969).
The relationship between calcium homeostasis, mitochondrial
activity and Aβ formation is rather complex. It is established that
the modulation of ER calcium homeostasis can affect mitochon-
drial function25 and APP metabolism.30 On the other hand, Aβ
pathology and mitochondrial dysfunction can also disrupt intracel-
lular calcium homeostasis.58,59 In addition, Aβ can impair mitochon-
drial function, and, at the same time, mitochondrial failure can
promote Aβ formation.60 As the direct molecular target(s)
of tetrahydrocarbazoles remains elusive, this study is limited by
Figure 5. Dose-dependent effects of tetrahydrocarbazole derivatives on Aβ production. (a) Chemical structure of three promising synthesized
tetrahydrocarbazole analogs. The effect of the three select synthesized tetrahydrocarbazoles on the production of (b) Aβ38, (c) Aβ40 and (d)
Aβ42 peptides tested at six different concentrations in APPsw/PS1-M146L-expressing HEK293 cells. The IC50 of all Aβ species for all derivative
structures tested lies at low micromolar range. All the values are normalized to the value of DMSO, which is set to 1. DMSO, dimethyl sulfoxide.
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the fact that we cannot conclude that the improved mitochondrial
activity and decreased Aβ production are necessarily downstream
effects of normalizing calcium homeostasis. Alternatively,
improved mitochondrial function and/or decreased Aβ generation
can be upstream of normalized intracellular calcium homeostasis.
Therefore, future studies addressing the exact molecular target(s)
of tetrahydrocarbazole lead structure and their detailed thera-
peutic mode of action are of utmost importance. Whether or not
the beneficial effects of tetrahydrocarbazoles on calcium home-
ostasis, mitochondrial function and APP processing follow a
dependency, should not, however, impact the therapeutic
relevance of this discovery. Another important open question
which remains to be elucidated is whether tetrahydrocarbazoles
also reverse the late-stage Aβ-plaque-dependent calcium dis-
turbances in the brain.61,62 Apart from IP3 receptor channel gating
itself,63 multiple upstream elements of IP3R-mediated calcium
release are affected in AD, for example, GPCR in general,64 and
muscarinic receptors in particular,65 G-proteins,66 as well as PLC.67
Given that tetrahydrocarbazoles may potentially target any of
those upstream elements, such a phenotypic multitargeted drug
screening assay provides the important advantage of collectively
addressing several aspects of AD.
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